Publicaciones en las que colabora con Laura Rosiñol Dachs (9)

2024

  1. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

    Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096

2023

  1. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study

    The Lancet Oncology, Vol. 24, Núm. 8, pp. 913-924

2022

  1. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study

    European Journal of Cancer, Vol. 174, pp. 243-250

2020

  1. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma

    Leukemia, Vol. 34, Núm. 11, pp. 3007-3018

  2. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

    Blood, Vol. 136, Núm. 2, pp. 199-209

2016

  1. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under lendex: A longitudinal analysis

    Blood, Vol. 127, Núm. 9, pp. 1151-1162

  2. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial

    The Lancet Oncology, Vol. 17, Núm. 8, pp. 1127-1136

2013

  1. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma

    New England Journal of Medicine, Vol. 369, Núm. 5, pp. 438-447

2010

  1. Utilización de bisfosfonatos en pacientes con mieloma múltiple: recomendaciones del comité de expertos del Grupo Español de Mieloma del Programa Español de Tratamientos en Hematología

    Medicina Clinica, Vol. 134, Núm. 6, pp. 268-278